ReCET trial enrollment puts Endogenex in focus for gut-targeted diabetes care
Endogenex has completed enrollment in the ReCET Clinical Study, a pivotal evaluation of the Endogenex System in adults with type 2 diabetes whose blood glucose levels remain inadequately controlled on non-insulin glucose-lowering medications. The study has enrolled 350 patients across approximately 40 sites in the United States and Australia, moving the clinical-stage medical device developer